Sana biotechnology announces preclinical data published in nature communications demonstrating the ability of its hypoimmune allogeneic cd19-directed car t cells to evade immune rejection and produce durable anti-tumor responses

Hypoimmune-modified allogeneic cd19-directed car t cells can evade immune detection and kill tumor cells in a novel humanized allogeneic preclinical model in vivo, including following tumor cell reinjection
SANA Ratings Summary
SANA Quant Ranking